PMDA drug package insert
ベザフィブラート徐放錠100mg「トーワ」
PMDA Prescription drug · 東和薬品株式会社 · package insert Sep 14, 2023
Key facts
| Brand names | ベザフィブラート徐放錠100mg「トーワ」, ベザフィブラート徐放錠200mg「トーワ」 |
|---|---|
| Nonproprietary names | ベザフィブラート |
| Companies | 製造販売元／東和薬品株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 高脂血症治療剤 |
| Therapeutic category codes | 872183 |
| YJ codes | 2183005G2168, 2183005G1307 |
| Approval numbers | 22500AMX01219, 22500AMX01220 |
| Package insert edition | 第1版 |
| Package insert date | Sep 14, 2023 |
| PMDA document key | 480235_2183005G1307_1 |
| PMDA company code | 480235 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: